ClinicalTrials.gg
CompletedNCT04804540Updated Feb 12, 2025Results posted

A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

A Phase 4 interventional study of Vedolizumab IV in Ulcerative Colitis and Crohn Disease, sponsored by Takeda. Completed at 17 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
16th of 38
150 · median 110
Started
2021
with 4 others
Phase 4
15 of 38
2 open now
Registered
28th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 16th largest by enrollment, is one of 5 that started in 2021, is one of 15 in phase 4, and was the 28th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, people with ulcerative colitis or Crohn's disease will be treated with vedolizumab. The main aim of the study is to check for side effects from vedolizumab.

At the first visit, the study doctor will check who can take part. Participants will receive vedolizumab slowly through a vein (infusion). Participants will regularly visit the clinic for up to 46 weeks for more infusions of Vedolizumab. During these visits, the study doctor will check if there are any side effects from this treatment.

Participants will visit the clinic for a final check-up up to 16 weeks after their final infusion of Vedolizumab. Clinic staff will arrange a phone call 6 months after their final infusion of Vedolizumab for a further check-up.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have active UC or CD.

The study will enroll approximately 150 patients. Participants will be assigned to the vedolizumab treatment group.

•Vedolizumab 300 mg

Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2, 6 and 10 (CD-participants who have not shown a response can receive a dose at Week 10) during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.

This multicentre trial will be conducted in India. The overall time to participate in this study is 74 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone plus a final visit after receiving their last dose of drug for a follow-up assessment.

03

Conditions studied

  • Ulcerative Colitis
  • Crohn Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) at least 3 months prior to screening, with a Full Mayo Score of 6-12 for UC and a Harvey Bradshaw Index (HBI) score of >=8 for CD at the time of enrolment.
  2. Has demonstrated, an inadequate response to, loss of response to, or intolerance to at least 1 of the following agents:

    1. Conventional therapy
    2. TNF-α alpha antagonist

Exclusion criteria

Exclusion Criteria:

  1. Has undergone an ileostomy, colostomy, or has known fixed symptomatic stenosis of the intestine.
  2. Has active or latent tuberculosis (TB).
  3. Has had a prior exposure to vedolizumab or a history of or allergies to vedolizumab, natalizumab, efalizumab, or rituximab.
  4. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during screening or prior to the administration of study drug on Day 1.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg

    Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.

    Drug: Vedolizumab IV

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    AE was defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with the treatment. AE can therefore be any unfavourable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of a drug, whether or not it is considered related to the drug. A SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI (serious or nonserious) was one of scientific and medical concern specific to the compound or program.

    Time frame: From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)

  2. Number of Participants With Adverse Drug Reactions (ADRs) and Unexpected ADRs

    An ADR was an AE for which there was at least a reasonable suspicion of a causal relationship between an AE and a suspected medicinal product. An unexpected ADR was an ADR with the nature, severity, or outcome which was not consistent with the product insert.

    Time frame: From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)

Secondary outcomes

  1. Percentage of UC Participants With Clinical Response at Weeks 14, 30 and 46

    Clinical response for UC participants was defined as decrease in Simple Clinical Colitis Activity Index (SCCAI) of greater than and equal to (\>=) 3 from baseline or by physician assessment of clinical response. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.

    Time frame: At Weeks 14, 30 and 46

  2. Percentage of CD Participants With Clinical Response at Weeks 14, 30 and 46

    Clinical response for CD participants was defined as decrease in Harvey Bradshaw Index (HBI) of \>= 3 points from baseline. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.

    Time frame: At Weeks 14, 30 and 46

  3. Percentage of UC Participants With Clinical Remission at Weeks 14, 30 and 46

    Clinical remission for UC participants was defined as decrease in SCCAI of less than and equal to (\<=) 2 with no individual score \> 1. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.

    Time frame: At Weeks 14, 30 and 46

  4. Percentage of CD Participants With Clinical Remission at Weeks 14, 30 and 46

    Clinical remission for CD participants was defined as HBI of \<= 4. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.

    Time frame: At Weeks 14, 30 and 46

  5. Percentage of UC and CD Participants Who Discontinued Vedolizumab

    Vedolizumab discontinuation was defined as ceasing vedolizumab, or a treatment gap \>= 90 days between consecutive doses.

    Time frame: From first dose of study drug up to Week 46

  6. Percentage of UC Participants With Mucosal Healing at Week 46

    Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Mayo endoscopic sub-score of \<=1 point. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranged from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 were considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, with higher scores indicated more severe disease.

    Time frame: At Week 46

  7. Percentage of CD Participants With Mucosal Healing at Week 46

    Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Simple Endoscopic Score for Crohn Disease (SES-CD) 0-2 or SES-CD \<=4 and at least a 2-point reduction from baseline with no sub-score \>1. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranging from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.

    Time frame: At Week 46

  8. Percentage of UC Participants With Endoscopic Response at Week 46

    Endoscopic response was defined as decrease in Mayo endoscopic sub-score of \>=1 point in UC participants. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranges from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 are considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, where higher scores indicated more severe disease.

    Time frame: At Week 46

  9. Percentage of CD Participants With Endoscopic Response at Week 46

    Endoscopic response was defined as \> 50% decrease in SES-CD in CD participants. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranged from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.

    Time frame: At Week 46

  10. Change From Baseline in Patient-reported Quality of Life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]) Scores at Weeks 14, 30, and 46

    The SIBDQ was a valid and reliable instrument used to assess quality of life in adult participants with Inflammatory Bowel Disease (IBD). It was a 10-item questionnaire that included questions on 4 domains of health-related quality of life (HRQoL): bowel systems, emotional function, social function, and systemic function and was scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). A total SIBDQ score was calculated by summing the scores from each domain; the total SIBDQ score ranged from 10 (poor HRQoL) to 70 (optimum HRQoL). Higher values of SIBDQ represented a better quality of life.

    Time frame: Baseline, Weeks 14, 30 and 46

07

Results

Posted Feb 12, 2025

Participant flow

Participants took part in the study at the 17 investigative sites in India from 08 December 2021 to 02 February 2024.

Participant flow — Overall Study
MilestoneUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Started10248
Completed7635
Not completed2613
Withdrew: Adverse event2613

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

AE was defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with the treatment. AE can therefore be any unfavourable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of a drug, whether or not it is considered related to the drug. A SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. An AESI (serious or nonserious) was one of scientific and medical concern specific to the compound or program.

Time frame:
From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Participants with AEs5429
Participants with SAEs62
Participants with AESIs40
PrimaryNumber of Participants With Adverse Drug Reactions (ADRs) and Unexpected ADRs

An ADR was an AE for which there was at least a reasonable suspicion of a causal relationship between an AE and a suspected medicinal product. An unexpected ADR was an ADR with the nature, severity, or outcome which was not consistent with the product insert.

Time frame:
From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Drug Reactions (ADRs) and Unexpected ADRs
ParticipantsUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Participants with ADRs50
Participants with Unexpected ADRs20
SecondaryPercentage of UC Participants With Clinical Response at Weeks 14, 30 and 46

Clinical response for UC participants was defined as decrease in Simple Clinical Colitis Activity Index (SCCAI) of greater than and equal to (\>=) 3 from baseline or by physician assessment of clinical response. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.

Time frame:
At Weeks 14, 30 and 46
Reported as:
Number · percentage of participants
Percentage of UC Participants With Clinical Response at Weeks 14, 30 and 46
percentage of participantsUC Participants: Vedolizumab 300 mg
At Week 1454.9 (44.7 to 64.8)
At Week 3062.7 (52.6 to 72.1)
At Week 4673.5 (63.9 to 81.8)
SecondaryPercentage of CD Participants With Clinical Response at Weeks 14, 30 and 46

Clinical response for CD participants was defined as decrease in Harvey Bradshaw Index (HBI) of \>= 3 points from baseline. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.

Time frame:
At Weeks 14, 30 and 46
Reported as:
Number · percentage of participants
Percentage of CD Participants With Clinical Response at Weeks 14, 30 and 46
percentage of participantsCD Participants: Vedolizumab 300 mg
At Week 1472.9 (58.2 to 84.7)
At Week 3070.8 (55.9 to 83.0)
At Week 4668.8 (53.7 to 81.3)
SecondaryPercentage of UC Participants With Clinical Remission at Weeks 14, 30 and 46

Clinical remission for UC participants was defined as decrease in SCCAI of less than and equal to (\<=) 2 with no individual score \> 1. The SCCAI consists of five colitis activity symptom items (bowel frequency per day, bowel frequency per night, urgency of defecation, blood in stool, and general well-being) along with an assessment of extracolonic manifestations. Bowel frequency per night is scored on a 0-2 scale and General well-being is scored on a 0-4 scale. The other 3 symptom scores are scored on a 0-3 scale. 1 point each is added for the presence of any extracolonic manifestation (i.e., arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis). The total overall possible scoring range was 0-19 with increasing scores being indicative of more colitis activity.

Time frame:
At Weeks 14, 30 and 46
Reported as:
Number · percentage of participants
Percentage of UC Participants With Clinical Remission at Weeks 14, 30 and 46
percentage of participantsUC Participants: Vedolizumab 300 mg
At Week 1439.2 (29.7 to 49.4)
At Week 3043.1 (33.4 to 53.3)
At Week 4652.0 (41.8 to 62.0)
SecondaryPercentage of CD Participants With Clinical Remission at Weeks 14, 30 and 46

Clinical remission for CD participants was defined as HBI of \<= 4. HBI was composed of five clinical parameters: general well-being (0-4, where higher score means lower wellbeing), abdominal pain (0-3, higher score means more severe pain), number of liquid stools/day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score was the sum of individual parameters. The score ranged from a minimum score of 0 to no pre-specified maximum score as it depended on the number of liquid stools, where higher scores indicated more severe disease. The score \< 5 is considered as clinical remission, 5-7 mild, 8-16 moderate, and \>16 severe disease. A higher score indicated a worse outcome.

Time frame:
At Weeks 14, 30 and 46
Reported as:
Number · percentage of participants
Percentage of CD Participants With Clinical Remission at Weeks 14, 30 and 46
percentage of participantsCD Participants: Vedolizumab 300 mg
At Week 1447.9 (33.3 to 62.8)
At Week 3045.8 (31.4 to 60.8)
At Week 4656.3 (41.2 to 70.5)
SecondaryPercentage of UC and CD Participants Who Discontinued Vedolizumab

Vedolizumab discontinuation was defined as ceasing vedolizumab, or a treatment gap \>= 90 days between consecutive doses.

Time frame:
From first dose of study drug up to Week 46
Reported as:
Number · percentage of participants
Percentage of UC and CD Participants Who Discontinued Vedolizumab
percentage of participantsUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Percentage of UC and CD Participants Who Discontinued Vedolizumab25.5 (17.4 to 35.1)27.1 (15.3 to 41.8)
SecondaryPercentage of UC Participants With Mucosal Healing at Week 46

Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Mayo endoscopic sub-score of \<=1 point. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranged from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 were considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, with higher scores indicated more severe disease.

Time frame:
At Week 46
Reported as:
Number · percentage of participants
Percentage of UC Participants With Mucosal Healing at Week 46
percentage of participantsUC Participants: Vedolizumab 300 mg
Percentage of UC Participants With Mucosal Healing at Week 4622.5 (14.9 to 31.9)
SecondaryPercentage of CD Participants With Mucosal Healing at Week 46

Mucosal healing was based on endoscopic evidence of no inflammation and healing of the mucosa as defined by a Simple Endoscopic Score for Crohn Disease (SES-CD) 0-2 or SES-CD \<=4 and at least a 2-point reduction from baseline with no sub-score \>1. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranging from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.

Time frame:
At Week 46
Reported as:
Number · percentage of participants
Percentage of CD Participants With Mucosal Healing at Week 46
percentage of participantsCD Participants: Vedolizumab 300 mg
Percentage of CD Participants With Mucosal Healing at Week 468.3 (2.3 to 20.0)
SecondaryPercentage of UC Participants With Endoscopic Response at Week 46

Endoscopic response was defined as decrease in Mayo endoscopic sub-score of \>=1 point in UC participants. Full Mayo Score evaluated ulcerative colitis stage, based on four parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score (including Mayo endoscopic sub-score) ranges from 0 (normal or inactive disease) to 3 (severe activity) yielding a total score of 0-12. The scores 0-2 are considered as clinical remission, 3-5 mild, 6-10 moderate, and 11-12 severe, where higher scores indicated more severe disease.

Time frame:
At Week 46
Reported as:
Number · percentage of participants
Percentage of UC Participants With Endoscopic Response at Week 46
percentage of participantsUC Participants: Vedolizumab 300 mg
Percentage of UC Participants With Endoscopic Response at Week 4621.6 (14.0 to 30.8)
SecondaryPercentage of CD Participants With Endoscopic Response at Week 46

Endoscopic response was defined as \> 50% decrease in SES-CD in CD participants. SES-CD assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension, and the presence and type of narrowings. Each of the four SES-CD variables was scored from 0 to 3, with the sum of scores for each variable ranged from 0 to 15 yielding a total SES-CD score of 0-60, where higher scores indicated more severe disease.

Time frame:
At Week 46
Reported as:
Number · percentage of participants
Percentage of CD Participants With Endoscopic Response at Week 46
percentage of participantsCD Participants: Vedolizumab 300 mg
Percentage of CD Participants With Endoscopic Response at Week 4612.5 (4.7 to 25.2)
SecondaryChange From Baseline in Patient-reported Quality of Life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]) Scores at Weeks 14, 30, and 46

The SIBDQ was a valid and reliable instrument used to assess quality of life in adult participants with Inflammatory Bowel Disease (IBD). It was a 10-item questionnaire that included questions on 4 domains of health-related quality of life (HRQoL): bowel systems, emotional function, social function, and systemic function and was scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). A total SIBDQ score was calculated by summing the scores from each domain; the total SIBDQ score ranged from 10 (poor HRQoL) to 70 (optimum HRQoL). Higher values of SIBDQ represented a better quality of life.

Time frame:
Baseline, Weeks 14, 30 and 46
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Quality of Life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]) Scores at Weeks 14, 30, and 46
score on a scaleUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Change at Week 148.4 ± 12.918.3 ± 12.24
Change at Week 3012.9 ± 13.168.4 ± 14.31
Change at Week 4613.0 ± 12.8410.6 ± 15.91

Adverse events

Collected over From first dose of study drug up to 24 weeks after the last dose (up to 70 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UC Participants: Vedolizumab 300 mg0/102 (0%)6/102 (5.9%)25/102 (24.5%)
CD Participants: Vedolizumab 300 mg0/48 (0%)2/48 (4.2%)19/48 (39.6%)
Most frequent serious events
Most frequent serious events
EventUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
Intestinal obstructionGastrointestinal disorders0/1021/48
Small intestinal obstructionGastrointestinal disorders1/1021/48
CholelithiasisHepatobiliary disorders1/1020/48
Colitis ulcerativeGastrointestinal disorders1/1020/48
Pulmonary tuberculosisInfections and infestations1/1020/48
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/48
Tuberculous pleurisyInfections and infestations1/1020/48
Most frequent other events
Most frequent other events
EventUC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mg
AnaemiaBlood and lymphatic system disorders8/1026/48
PyrexiaGeneral disorders7/1026/48
HeadacheNervous system disorders5/1024/48
VomitingGastrointestinal disorders0/1024/48
Colitis ulcerativeGastrointestinal disorders7/1020/48
Aphthous ulcerGastrointestinal disorders0/1023/48
DizzinessNervous system disorders3/1023/48

Baseline characteristics

The Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)UC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mgTotal
Mean38.55 ± 11.19032.60 ± 10.84936.65 ± 11.391
Sex: Female, Male
Sex: Female, Male(Participants)UC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mgTotal
Female353267
Male671683
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UC Participants: Vedolizumab 300 mgCD Participants: Vedolizumab 300 mgTotal
Race — Indian10248150
08

Study locations

17 sites
  • Government General Hospital
    Guntur, Andhra Pradesh 522001, India
  • Institute of Gastroenterology and Liver Disease Dispur Hospitals
    Guwahati, Assam 781006, India
  • Indira Gandhi Institute of Medical Sciences
    Patna, Bihar 800014, India
  • Dr. Ram Manohar Lohia Hospita Hospital
    New Delhi, Delhi 110001, India
  • Maulana Azad Medical college & Associated G B Pant Hospital
    New Delhi, Delhi 110002, India
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
  • Gastroplus Digestive Disease Centre Pvt.Ltd
    Ahmedabad, Gujarat 380054, India
  • Surat Institute of Digestive Sciences
    Surat, Gujarat 395002, India
  • Banglore Medical College & Research Institute
    Bangalore, Karnatka 560002, India
  • Midas Multispeciality Hospital
    Nagpur, Maharashtra 440010, India
  • Dayanand Medical College and Hospital
    Ludhiana, Punjab 141001, India
  • VGM Hospital- Institute of Gastroenterology
    Coimbatore, Tamilnadu 641005, India
  • Asian Institute of Gastroenterology
    Hyderabad, Telangana 500082, India
  • Yashoda Hospitals
    Secunderabad, Telangana 500003, India
  • King George's Medical University
    Lucknow, Uttar Pradesh 226003, India
  • Osmania General Hospital
    Hyderabad, 500012, India
  • Deccan College of Medical Sciences
    Hyderabad, 500058, India
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2024, 25 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 63 phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 63. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 18, 2021
StartActual
Dec 8, 2021
Primary completionActual
Feb 2, 2024
CompletionActual
Feb 2, 2024
Results first posted
Feb 12, 2025
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04804540
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Dec 8, 2021
Primary completion
Feb 2, 2024
Completion
Feb 2, 2024
Results posted
Feb 12, 2025
Last update
Feb 12, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion